M. Herold et al., Successful treatment and re-treatment of resistant B-cell chronic lymphocytic leukemia with the monoclonal anti-CD 20 antibody rituximab, ANN HEMATOL, 79(6), 2000, pp. 332-335
We report on two patients with chemoresistant B-cell chronic lymphocytic le
ukemia who were treated successfully with the monoclonal anti-CD 20 antibod
y rituximab. Both patients suffered from severe thrombocytopenia requiring
platelet transfusions over a period of several months. Neither chemotherapy
nor immunosuppressive agents (corticolds, immunoglobulins) were effective.
After four doses of rituximab (375 mg/m(2) weekly), both patients recovere
d within a few weeks to hematological partial remission. One patient was re
-treated successfully three times after relapses. Both patients were premed
icated with prednisone (100 mg) 30 min prior to the infusion to prevent cyt
okine release and the antibody infusions were well tolerated.